



PATIENT

Jack Harrington

SPECIES

Canine

BREED

Chihuahua

SEX

Male Neutered

AGE

11.2 years

WEIGHT

8lbs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

Loetitia St-Jacques,
LVT/RVT

HOSPITAL NAME

Grass Valley
Veterinary Hospital

REFERRING VET

Dr. Cortright

INVOICE

25101

DATE

6/30/22

PRESENTING CLINICAL SIGNS

History: Recheck echo. Grade 4-5/6 heart murmur. Heavy breathing.
-Current medications: Pimobendan 2.5 ½ tab PO BID.
-Pertinent previous echo findings (2020 CS): CVD B2 with MR and TR.

ECHOCARDIOGRAM FINDINGS

2D, m-mode and Doppler imaging are available. Diffuse thickening of mitral valve leaflets (anterior > posterior) with prolapse into the left atrial lumen. Severe eccentric mitral regurgitation with severe left atrial dilation. Significant LV dilation with hyperdynamic myocardial function. The tricuspid valve appears thickened with septal prolapse and mild tricuspid regurgitation. Velocity consistent with mild to moderate pulmonary hypertension. Mild right atrial and ventricular dilation consistent with early pulmonary arterial hypertension. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities. No pulmonic or aortic insufficiency. No pericardial or pleural effusion noted. No cardiac tumors observed.

CARDIAC CHART

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.5	3.5	NM	2.5	44	80	NM
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	NM	1.4	0.9	3.9	2.4	3.6	2.0
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
<i>*Note: All measurements based upon multi-modal images and methods. An average value is reported.</i>				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Chronic degenerative valve disease persists with evidence of progression. Severe mitral and mild tricuspid regurgitation are noted with severe left heart enlargement. Severe LA dilation indicates the risk for spontaneous congestive heart failure is elevated. Mild TR is also noted, with evidence of mild to moderate pulmonary hypertension. No additional issues such as systolic dysfunction are identified.

Even without reported clinical signs the degree of disease seen here is marked, and full lifelong cardiac support is recommended as below including Lasix therapy. Depending on clinical



PATIENT

Jack Harrington

SPECIES

Canine

BREED

Chihuahua

SEX

Male Neutered

AGE

11.2 years

WEIGHT

8lbs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

Loetitia St-Jacques,
LVT/RVT

HOSPITAL NAME

Grass Valley
Veterinary Hospital

REFERRING VET

Dr. Cortright

INVOICE

25101

DATE

6/30/22

response to the medications, cough suppression may also be useful. **Monitoring of sleeping breathing rates in the future will be paramount to determine the origin of any future cough.** The average survival of canine patients with active pulmonary edema is 8-9 months on medications, however they generally are able to maintain a good quality of life for that period. Patient will always be at risk for recurrent CHF, development of arrhythmias/LA tear, syncope and/or sudden death in the future. Monitoring of renal values is recommended lifelong.

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for development of a worsening cough, labored breathing, exercise intolerance or collapse episodes.


PLAN

Screening BP is recommended. Continue Pimobendan 0.3mg/kg PO q12h. Administer low dose furosemide/Lasix 1 mg/kg PO q12h. Administer spironolactone 1-2mg/kg PO q12h. Consider hydrocodone with homatropine (0.2-0.4mg/kg PO up to q4-6 hours PRN) if cough persists despite normal SRRs.

A renal panel and BP are recommended in 10-14 days, then every 3-4 months on diuretics to ensure tolerance of medications. If doing well at that time and BP >130mmHg, institute ACEI 0.5mg/kg PO q12h.

A recheck echocardiogram is recommended in 6 months to screen for progression, sooner if clinical signs arise/persist.

IMAGES



The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com